FAGR Fagron SA

Fagron shareholders approve all voting items AGM

Fagron shareholders approve all voting items AGM

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 12 May 2025 – 7PM CET

Fagron shareholders approve all voting items AGM

Fagron, the leading global player in pharmaceutical compounding, held its annual general shareholders meeting today, where all the voting items were approved.

Resolutions

The annual general meeting approved, amongst other things, Fagron’s annual financial statements and dividend proposal of €0.35 per share for the fiscal year 2024, the remuneration policy and the appointment of the statutory auditor for the financial years 2025 up to and including 2027. The meeting also approved the proposed reappointment of Ann Desender BV as independent non-executive director until the annual general meeting of the year 2029.

Meeting and meeting documents

All meeting documents for both meetings are available on Fagron’s . The minutes of the meetings will also be made available on the website.

Dividend calendar

The dividend calendar is as follows:

  • Ex-dividend date: 19 May 2025
  • Record date: 20 May 2025
  • Payment date: 21 May 2025



Further information

About Fagron

Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 30 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment



EN
12/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fagron SA

Fagron NV: 1 director

Five Directors at Fagron NV bought/sold 189,367 shares at between 16.230EUR and 20.506EUR. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...

 PRESS RELEASE

Fagron shareholders approve all voting items AGM

Fagron shareholders approve all voting items AGM Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 May 2025 – 7PM CET Fagron shareholders approve all voting items AGM Fagron, the leading global player in pharmaceutical compounding, held its annual general shareholders meeting today, where all the voting items were approved. ResolutionsThe annual general meeting approved, amongst other things, Fagron’s annual financial statements and dividend proposal of €0.35 per share for the fiscal year 2024, the remuneration policy and the appointment of the statutory auditor fo...

 PRESS RELEASE

Aandeelhouders Fagron keuren alle agendapunten van de jaarvergadering ...

Aandeelhouders Fagron keuren alle agendapunten van de jaarvergadering goed Gereglementeerde informatieNazareth (België)/Rotterdam (Nederland), 12 mei 2025 – 19:00u CET Aandeelhouders Fagron keuren alle agendapunten van de jaarvergadering goed Fagron, de toonaangevende mondiale speler in farmaceutische bereidingen, hield vandaag haar jaarlijkse algemene vergadering van aandeelhouders, waarbij alle ingediende voorstellen werden goedgekeurd. BesluitenDe jaarvergadering heeft onder andere Fagron’s jaarrekening en het dividendvoorstel van €0,35 per aandeel over het boekjaar 2024, het remunera...

Guy Sips ... (+7)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Lewi
Thomas Vranken
  • Thomas Vranken

Fagron Capital Markets Day feedback

Yesterday, Fagron hosted a Capital Markets Day where it laid out its strategic priorities for 2030. We see the updated Compounding for Growth strategy as a natural extension of the successful current trajectory. Financial targets are set for HSD-LDD organic CER revenue growth, a 21.0% REBITDA margin by 2027 progressively increasing thereafter to 2030, =70% operating cash conversion, =50% FCF conversion and 3.5% maintenance capex. Management continues to expect solid organic growth across all reg...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch